Trial Profile
A Pilot Study of Anlotinib for the Evaluation of Safety and Efficacy in Patients With Stage IV Natural Killer/T-cell Lymphoma and Refractory to L-asparaginase Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary)
- Indications T-cell lymphoma
- Focus Therapeutic Use
- 13 Sep 2021 Status changed from recruiting to completed.
- 27 Jan 2021 Planned End Date changed from 1 Jul 2021 to 1 Dec 2021.
- 27 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Jul 2021.